Quin, a women-owned company, is expanding its research and development of a pioneering Type 1 diabetes management app for people who are living with the condition, which requires individuals to self-administer insulin throughout the day to ensure HbA1c (average blood glucose level over three months) are as close to normal as possible.
Of the 3.8 million people who are currently living with diabetes in the UK, approximately 300,000 people are diagnosed with Type 1 Diabetes Mellitus (T1DM). As the molecular taxonomy for diabetes remains incomplete, current guidelines can only provide generic solutions as the factors that affect blood glucose are not fully understood. As a result, only 8% of this population achieve HbA1c targets with current diabetes management tools and devices.
People who take insulin are two to three times more likely to have fatigue, anxiety, stress and depression, due to the demands of diabetes. The Quin mobile medical app is taking an alternative approach to T1DM management. Using an artificial intelligence-powered algorithm, the app aims to help relieve the cognitive and psychological load of decision-making by tracking what may be affecting an individual’s blood glucose, and recalling what’s worked for them in the past to help them make the best possible self-care decisions.
Read more –> Pharmafield.co.uk